Dr. Stephen K. Tyring, MD PHD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 547
Licensed in Texas since 1983, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Texas Medical Branch at Galveston
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
TX license G5714 (first issued 1983; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Mays MD PA (3 clinicians)
- Dermatological Association of Texas PLLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 547
- Services billed
- 3,805
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 736 | 143 |
| Established patient office or other outpatient visit, 20-29 minutes | 668 | 454 |
| Destruction of skin growth, 1-14 growths | 274 | 223 |
| Destruction of precancer skin growth, 1 growth | 259 | 191 |
| Biopsy of related skin growth, first growth | 214 | 183 |
| Established patient office or other outpatient visit, 30-39 minutes | 197 | 153 |
| New patient office or other outpatient visit, 30-44 minutes | 178 | 178 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 80 | 56 |
| Biopsy of related skin growth, each additional growth | 80 | 55 |
| Destruction of precancer skin growth, 15 or more growths | 72 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Webster, TX | 341 |
| Ketoconazole Other prescribers in Webster, TX | 280 |
| Clobetasol Propionate Other prescribers in Webster, TX | 226 |
| Fluocinonide Other prescribers in Webster, TX | 139 |
| Doxycycline Hyclate Other prescribers in Webster, TX | 134 |
| Hydroxyzine Hcl Other prescribers in Webster, TX | 100 |
| Mupirocin Other prescribers in Webster, TX | 74 |
| Dupixent Pen (dupilumab) Other prescribers in Webster, TX | 62 |
| Clindamycin Phosphate Other prescribers in Webster, TX | 54 |
| Desonide | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 327 payments worth $106,392 in total to this clinician.
| AbbVie Inc. | $35,677 |
|---|---|
| Janssen Biotech, Inc. | $19,623 |
| Galderma Laboratories, L.P. | $14,841 |
| Pfizer Inc. | $11,313 |
| Regeneron Pharmaceuticals, Inc. | $10,364 |
| GlaxoSmithKline, LLC. | $7,172 |
| UCB, Inc. | $1,789 |
| Almirall LLC | $930 |
| Compensation for services other than consulting (speaking, faculty) | $71,470 |
|---|---|
| Consulting Fee | $21,783 |
| Food and Beverage | $8,052 |
| Travel and Lodging | $4,974 |
| Education | $113 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Galderma Laboratories, L.P. Sep 6, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $5,460 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,124 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,900 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,900 |
| AbbVie Inc. Jul 7, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,900 |
| Pfizer Inc. Mar 11, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $4,775 |
| Pfizer Inc. May 9, 2025 | Compensation for services other than consulting (speaking, faculty) LITFULO · IMMUNOLOGY | $4,275 |
| Janssen Biotech, Inc. Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| Janssen Biotech, Inc. May 31, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| Janssen Biotech, Inc. Nov 15, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
All 51 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Dec 8, 2025 | Education TREMFYA · Immunology · in-kind | $13.17 |
| Janssen Biotech, Inc. Nov 17, 2025 | Travel and Lodging TREMFYA · Immunology · travel to HOUSTON, TX | $35.70 |
| Janssen Biotech, Inc. Nov 15, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| Galderma Laboratories, L.P. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Sep 6, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $5,460 |
| Galderma Laboratories, L.P. Sep 6, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to DALLAS, TX · in-kind | $91.04 |
| GlaxoSmithKline, LLC. Aug 25, 2025 | Compensation for services other than consulting (speaking, faculty) SHINGRIX · VACCINES | $650 |
| Janssen Biotech, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| AbbVie Inc. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,100 |
| Galderma Laboratories, L.P. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $600 |
| Janssen Biotech, Inc. Jul 26, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,350 |
| Janssen Biotech, Inc. Jul 19, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| GlaxoSmithKline, LLC. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) SHINGRIX · VACCINES | $3,900 |
| GlaxoSmithKline, LLC. Jul 14, 2025 | Travel and Lodging SHINGRIX · VACCINES · travel to Frederick, MD | $67.50 |
| AbbVie Inc. Jul 7, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,900 |
| GlaxoSmithKline, LLC. Jun 26, 2025 | Travel and Lodging SHINGRIX · VACCINES · travel to Frederick, MD · in-kind | $1,582 |
| GlaxoSmithKline, LLC. Jun 26, 2025 | Travel and Lodging SHINGRIX · VACCINES · travel to Frederick, MD · in-kind | $210 |
| AbbVie Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $2,100 |
| AbbVie Inc. Jun 10, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $602 |
| Janssen Biotech, Inc. May 31, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| Almirall LLC May 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $930 |
| AbbVie Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,500 |
| Janssen Biotech, Inc. May 19, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,900 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $4,900 |
| Janssen Biotech, Inc. May 10, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,800 |
| Pfizer Inc. May 9, 2025 | Compensation for services other than consulting (speaking, faculty) LITFULO · IMMUNOLOGY | $4,275 |
| Pfizer Inc. May 8, 2025 | Travel and Lodging LITFULO · IMMUNOLOGY · travel to Houston, TX · in-kind | $30.80 |
| Galderma Laboratories, L.P. Apr 21, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to HOUSTON, TX · in-kind | $32.90 |
| AbbVie Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) SKYRIZI · IMMUNOLOGY | $3,500 |
| AbbVie Inc. Apr 17, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $494 |
| AbbVie Inc. Apr 17, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $331 |
| Pfizer Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology | $89.99 |
| AbbVie Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,500 |
| Galderma Laboratories, L.P. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Pfizer Inc. Mar 11, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $4,775 |
| GlaxoSmithKline, LLC. Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty) SHINGRIX · VACCINES | $650 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,124 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,416 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,708 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to DALLAS, TX · in-kind | $71.90 |
| Regeneron Pharmaceuticals, Inc. Feb 21, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to DALLAS, TX · in-kind | $44.40 |
| Janssen Biotech, Inc. Feb 10, 2025 | Travel and Lodging TREMFYA · Immunology · travel to HOUSTON, TX | $35.70 |
| Janssen Biotech, Inc. Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,050 |
| UCB, Inc. Feb 4, 2025 | Consulting Fee Bimzelx · Immunology | $1,300 |
| Pfizer Inc. Feb 1, 2025 | Travel and Lodging CIBINQO · Inflammation & Immunology · travel to Rosemont, IL · in-kind | $716 |
| Pfizer Inc. Feb 1, 2025 | Travel and Lodging CIBINQO · Inflammation & Immunology · travel to Rosemont, IL · in-kind | $588 |
| AbbVie Inc. Jan 28, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to CINCINNATI, OH · in-kind | $40.87 |
| AbbVie Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) RINVOQ · IMMUNOLOGY | $3,500 |
| Galderma Laboratories, L.P. Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $600 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) SPEVIGO · IMMUNOLOGY | $775 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 54 industry-funded studies in 2025, from 15 companies. The companies reported $1,216,078 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. · Active, not recruiting · NCT06468228 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
Sun Pharmaceutical Industries Inc. - A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopi…
Janssen Research & Development, LLC - M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. - A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
Sanofi US Services Inc. · Completed · NCT06073119 - A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Incyte Corporation - A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company · Completed · NCT06602219 - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Incyte Corporation - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.